Thus, it could be intriguing to know the following: (1) how LTB4 and IL-6 trans-signaling would affect cardiomyocytes and cardiac channels; (2) if the administration of an LTB4 inhibitor would reverse cardiac remodeling in obese and diabetic patients; (3) the differential expression of LTB4 and IL-6 in various adipose tissues and macrophages; (4) whether LTB4 could potentially influence myocardial fibrosis and instigate reentry circuits and fatal arrhythmias. The gene discussed is IL6; the disease is Myocardial fibrosis.